FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application For Phase 2 Study Of Oral TNF-α Inhibitor MYMD-1 In Rheumatoid Arthritis
Portfolio Pulse from Happy Mohamed
The FDA has accepted MyMD Pharmaceuticals' Investigational New Drug Application for a Phase 2 study of oral TNF-α inhibitor MYMD-1 in rheumatoid arthritis. The drug, which has shown promising results in Phase 2 studies for sarcopenia, could disrupt the $41 billion industry. The company is also advancing 3 clinical programs for MyMD-1 in chronic inflammatory conditions including Sarcopenia, RA and Hashimoto's Thyroiditis.
August 14, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MyMD Pharmaceuticals' MYMD-1 has been accepted by the FDA for a Phase 2 study in rheumatoid arthritis. This could potentially disrupt the $41 billion industry and provide a significant boost to the company.
The FDA's acceptance of MYMD-1 for a Phase 2 study in rheumatoid arthritis is a significant milestone for MyMD Pharmaceuticals. This could potentially disrupt the $41 billion industry and provide a significant boost to the company. The company's stock is likely to react positively to this news in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100